Skip to search formSkip to main contentSkip to account menu

SDZ HTF 919

Known as: HTF 919, SDZ HTF-919 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tegaserod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Tegaserod (HTF 919) stimulates gut motility in normal horses.
REASONS FOR PERFORMING STUDY It has been shown that the selective 5-HT4 receptor agonist tegaserod induces an increase in… 
2007
2007
Neurogastroenterology of tegaserod (HTF 919) in the submucosal division of the guinea‐pig and human enteric nervous system
Abstract  Actions of the 5‐HT4 serotonergic receptor partial agonist, tegaserod, were investigated on mucosal secretion in the… 
2003
2003
Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects
Tegaserod (HTF 919), a selective 5‐HT4 receptor partial agonist with promotile activity throughout the gastrointestinal tract, is… 
2001
2001
The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young
Tegaserod (HTF 919) is a selective 5‐HT4 receptor partial agonist in development for the treatment of irritable bowel syndrome. 
2001
2001
The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects
Tegaserod (HTF 919) is a highly specific 5‐HT4 receptor partial agonist that exhibits promotile activity throughout the… 
Highly Cited
2000
Highly Cited
2000
The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro‐oesophageal reflux disease
Tegaserod (HTF 919), a 5‐HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in… 
2000
2000
Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats
2000
2000
Tegaseroid (HTF 919), a partial 5-HT4 receptor agonist, accelerates gastrointestinal (GI) transit
Highly Cited
1999
Highly Cited
1999
Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart.
Tegaserod (HTF 919) is a new drug being developed for gastrointestinal motility disorders. Because other gastrointestinal… 
1999
1999
Effect of Meal Timing Not Critical for the Pharmacokinetics of Tegaserod (HTF 919)
This study assessed the pharmacokinetic profiles of administering tegaserod (HTF 919) at different time intervals with respect to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)